About coherus oncology inc - CHRS
Coherus Oncology, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of biosimilar therapeutics. Its products include UDENYCA and LOQTORZI. The company was founded by Dennis M. Lanfear, Stuart E. Builder, Dr. Alan Herman, Doug Farrar and Steve Glover in September 2010 and is headquartered in Redwood City, CA.
CHRS At a Glance
Coherus Oncology, Inc.
333 Twin Dolphin Drive
Redwood City, California 94065
| Phone | 1-650-649-3530 | Revenue | 42.17M | |
| Industry | Pharmaceuticals: Major | Net Income | -170,291,000.00 | |
| Sector | Health Technology | Employees | 147 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
CHRS Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 3.944 |
| Price to Book Ratio | 2.82 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -0.277 |
| Enterprise Value to Sales | 1.152 |
| Total Debt to Enterprise Value | 1.119 |
CHRS Efficiency
| Revenue/Employee | 286,884.354 |
| Income Per Employee | -1,158,442.177 |
| Receivables Turnover | 2.29 |
| Total Asset Turnover | 0.117 |
CHRS Liquidity
| Current Ratio | 1.472 |
| Quick Ratio | 1.45 |
| Cash Ratio | 1.226 |
CHRS Profitability
| Gross Margin | 57.939 |
| Operating Margin | -425.718 |
| Pretax Margin | -434.231 |
| Net Margin | -403.801 |
| Return on Assets | -50.824 |
| Return on Equity | N/A |
| Return on Total Capital | -158.717 |
| Return on Invested Capital | -132.044 |
CHRS Capital Structure
| Total Debt to Total Equity | 89.101 |
| Total Debt to Total Capital | 47.118 |
| Total Debt to Total Assets | 20.455 |
| Long-Term Debt to Equity | 86.105 |
| Long-Term Debt to Total Capital | 45.534 |